1158 / 1708
Contemporaneous Evolution of Systemic Therapy
in High Risk Neuroblastoma
HD chemo
+abmt
Differentiation
Therapy
-Cis-retinoic
acidB
Immunothera
py
-Anti-GD2,
IL2,
GMCSF
C
Target Therapies
-Crizotinib
D,F
Epigenetic Modifiers
-HDAC
H
, ATR
inhibitor
I
Targeted
Immunotherapy
-Antigen directed
CART
E,G
Intensified
TransplantF